MGTA-117 Antibody
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human
c-Kit/CD117
MGTA-117 (0.1-1.0 mg/kg) rapidly and selectively binds and depletes CD117+ cells (human hematopoietic stem cells and AML tumor cells) with IC50 s of <10 pM[1].
MGTA-117 effectively depletes more than 95% of human hematopoietic stem and progenitor cells (HSPCs) in AML murine models[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MGTA-117(3 & 10 mg/kg, once or 3 mg/kg, QODx2) significantly increases survival of a 2.4-2.7-fold in Kasumi-1 xenograft hNSG mice model[2].
MGTA-117 (3 & 10 mg/kg, once) significantly decreases peripheral tumor burden, delays tumor growth, and increases survival in AML PDX 1 (2-3.3 fold) and AML PDX 2 (1.3-1.8 fold) xenograft hNSG mice models[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[MGTA-117 Antibody]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)